NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

• US 20120238587A1
• Filed: 03/19/2012
• Published: 09/20/2012
• Est. Priority Date: 03/17/2011
• Status: Active Grant

• Current Assignee: CMG Pharmaceutical CO.,LTD, Sungkwang Medical Foundation
• Original Assignee: Chemizon, A Division Of Optomagic Co., Ltd.
• Inventors: Gyorkos, Albert Charles, Cho, Suk Young, Choi, Eun Kyung, Lee, Gilnam, Lim, Chul Soo, Cho, Han Won, Seo, Jeongbeob, Kim, Choung Soo, Hwang, Jung Jin
• Granted Patent: US 8,664,230 B2
• Time in Patent Office: Days
• US Class Current: 514/255.05
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.

Claims

1. A compound of formula I,

2. A compound according to claim 1 which is selected from the following

3. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any of claims 1 to 2 or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof, and a pharmaceutically acceptable carrier.

4. Use of a compound of any of claims 1 to 2 or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for inhibiting PI3K enzyme.

5. Use of a compound of any of claims 1 to 2 or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for the treatment or prophylaxis of a PI3K mediated disorder or disease

6. Use of a compound of any of claims 1 to 2 or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for the treatment or prophylaxis of proliferative disorders.

7. Use of claim 6, wherein the proliferative disorders are selected from the group consisting of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.